Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 13Carcinoma, Renal Cell 6Tuberous Sclerosis 5Neoplasm Metastasis 5Hodgkin Disease 5Glioblastoma 5Colorectal Neoplasms 5Central Nervous System Neoplasms 5Waldenstrom Macroglobulinemia 4Stomach Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Lymphoma, Mantle-Cell 4Head and Neck Neoplasms 4Gliosarcoma 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sezary Syndrome 3Recurrence 3Prostatic Neoplasms 3Neoplasms 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Kidney Neoplasms 3

Interventions

Cyclophosphamide 19fludarabine 18Tacrolimus 10Whole-Body Irradiation 9Mycophenolic Acid 8venetoclax 7fludarabine phosphate 7Sirolimus 7Azacitidine 7Mesna 5Dexamethasone 5Bortezomib 5Rituximab 4Methotrexate 4Busulfan 4daratumumab 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Melphalan 3Lenalidomide 3Filgrastim 3Cytarabine 3Biopsy 3Alemtuzumab 3AP 1903 reagent 3pomalidomide 2merphos 2isatuximab 2ibrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hematologic Neoplasms × Everolimus × Clear all
NCT00935792 2017-09-26

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic

Phase 1/2 Completed
28 enrolled 13 charts
Other hematologic neoplasm

Leukemia, Lymphoid, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡